Morning Overview on MSN
The FDA cleared a new pill for an aggressive lung cancer that had stopped responding
Adults with a specific type of aggressive lung cancer that had stopped responding to platinum chemotherapy now have a new ...
A study published in the journal Function highlights the importance of not investigating exon splicing in isolation. Exon splicing is the process by which introns are removed from pre-mRNA and exons ...
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer Patients with ...
New research has shown that RNA-based testing can improve the detection and interpretation of clinically actionable genomic alterations that lead to MET exon 14 skipping in patients with lung ...
BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today ...
A new company, Ascidian Therapeutics, is launching with a focus on treating human diseases by rewriting RNA. With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology ...
Hereditary conditions cause those who suffer from them to live shorter lives with traumatic health issues. Because of this, researchers in the field of genetics are constantly exploring and developing ...
A new study describes the structure of a crucial enzyme present in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for coronavirus disease 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results